With the help of the 'Traditional Chinese Medicine Specialty Alliance Platform-Multicenter RCT Clinical Research Database,' this platform can be used to conduct scientific research on various aspects of DKD, such as disease prediction, treatment effectiveness evaluation, and recurrence rate analysis, providing effective means to improve DKD remission rates, delay disease progression, and enhance patients' quality of life. By selecting the Jiade Yishen Xiaozheng Qufang formula and conducting multicenter, prospective, double-blind RCT studies, its clinical value in improving DKD remission rates can be verified. With the support of scientific research, DKD treatment strategies can be optimized, therapeutic efficacy improved, recurrence rates reduced, and disease progression delayed, thereby enhancing patients' quality of life.
Meets the clinical diagnostic criteria for diabetic nephropathy;
Aged 18-75 years, any gender;
eGFR >45 ml/min/1.73m²;
24-hour urine protein <2.0 g/day;
Acute kidney injury or renal function impairment caused by other reasons (recent rapid decline in renal function, or kidney damage caused by drugs, infections, etc.);
Other primary or secondary kidney diseases (such as systemic lupus erythematosus, polycystic kidney disease, etc.);
Uncontrolled severe complications (such as severe cardiovascular disease, uncontrolled hypertension, severe infections, etc.);
Critical organ failure (severe diseases of the heart, liver, or lungs);
Jiazhen Yin
Lead sponsor
Hangzhou Hospital of Traditional Chinese Medicine
Sponsor institution